1-855-RxRxCSS / 1-855-797-9277

Clinical Trials

print-iconemail-iconshare-icon

As part of our mission to deliver the latest medical breakthroughs, the Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network physicians conduct clinical trials that test new treatments for different patients and cancer types. The following trials are coming soon to Chan Soon-Shiong Institute for Medicine at Mariposa.

Fill out my online form.

Open-label, Phase 1 Study of haNKĀ® for Infusion in Subjects With Metastatic or
Locally Advanced Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT03027128
Indication: Solid Tumors
NCT03027128 | QUILT-3.028


NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with TNBC Who Have Progressed on or After Standard-of-care Therapy
https://clinicaltrials.gov/ct2/show/NCT03387085
Indication: Triple Negative Breast Cancer
NCT03387085 | QUILT-3.067


NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy
https://clinicaltrials.gov/ct2/show/NCT03387111
Indication: Squamous Cell Carcinoma
NCT03387111 | QUILT-3.090


A Phase 1B/2 Trial of the NANT Pancreatic Cancer Vaccine as Treatment for Subjects with Pancreatic Cancer Who Have Progressed On Or After Standard-of-care Therapy
https://clinicaltrials.gov/ct2/show/NCT03586869
Indications: Pancreatic Cancer
NCT number: pending | QUILT 3.080


A NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with Standard-of-Care Therapy
https://clinicaltrials.gov/ct2/show/NCT03563157
Indication: Colorectal Cancer
NCT03563157 | QUILT 3.071


A NANT Hepatocellular Carcinoma (HCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC
https://clinicaltrials.gov/ct2/show/NCT03563170
Indication: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
NCT03563170 | QUILT 3.072


A Phase 2, Open-Label, Randomized Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC
https://clinicaltrials.gov/ct2/show/NCT03520686
Indications: Non Small Cell Lung Cancer
NCT03520686 | QUILT 2.023


A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
https://clinicaltrials.gov/ct2/show/NCT03228667
Indications: Non-Small Cell Lung Cancer
NCT03228667 | QUILT 3.055


A Phase 1 Trial of ABI-011 Administered Weekly in Patients with Advanced Solid Tumors or Lymphomas
https://clinicaltrials.gov/ct2/show/NCT02582827
Indication: Solid Tumors and Lymphomas
NCT02582827 | QUILT-3.014


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Clear Cell Sarcoma that Contains the EWSR1-ATF1 Gene Fusion
https://clinicaltrials.gov/ct2/show/NCT03132155
Indication: Clear Cell Sarcoma
NCT03132155 | QUILT-3.031


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Solid Tumors that Overexpress MET or Harbor MET EXON 14Skipping (METEX14DEL) Mutations
https://clinicaltrials.gov/ct2/show/NCT03147976
Indication: Solid Tumors
NCT03147976 | Quilt-3.036


Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02751528
Indications: HER2-low expressing (IHC 1+ or 2+) breast cancer
NCT02751528 | QUILT 3.013


An Open-label, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03127124
Indications: Pancreatic Adenocarcinoma
NCT03127124 | QUILT 2.022


NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03563144
Indications: Pancreatic Cancer
NCT03563144 | QUILT 3.088

For More Information

1-855-RxRxCSS

1-855-797-9277

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa
El Segundo
2040 East Mariposa Avenue
El Segundo, CA 90245

Costa Mesa (COMING SOON)
1640 Newport Blvd. Suite 370.
Costa Mesa, CA 92627

We are not currently accepting walk-ins. Please call to schedule an appointment.

For More Information

1-855-RxRxCSS

1-855-797-9277

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa
El Segundo
2040 East Mariposa Avenue
El Segundo, CA 90245

Costa Mesa (COMING SOON)
1640 Newport Blvd. Suite 370.
Costa Mesa, CA 92627

We are not currently accepting walk-ins. Please call to schedule an appointment.